[HTML][HTML] 阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析
王学敏， 张维红， 杜伟娇， 张新伟… - Chinese Journal of …, 2017 - ncbi.nlm.nih.gov
… in second or third-line is beneficial in PFS and OS when … making comparison between apatinib
monotherapy and … （epithelial growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs）…
monotherapy and … （epithelial growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs）…
[HTML][HTML] 埃克替尼对比标准二线化疗治疗晚期非小细胞肺癌的临床观察
姚舒洋， 钱坤， 王若天， 李元博， 张毅 - Chinese Journal of Lung …, 2015 - ncbi.nlm.nih.gov
… This study compared the efficacy and safety of icotinib with standard second-line … 表皮生长
因子受体（epidermal growth factor receptor, EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitors…
因子受体（epidermal growth factor receptor, EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitors…
[HTML][HTML] 老年晚期NSCLC 患者PD-1/PD-L1 免疫检查点抑制剂治疗现状及展望
MAO Yunye, S Shu, W An, Z Jinzhao… - Chinese Journal of …, 2024 - ncbi.nlm.nih.gov
… demonstrated that ICIs as monotherapy provide substantial benefits for patients aged 65-75
years, showing no significant difference compared to younger patients. … Second or third line …
years, showing no significant difference compared to younger patients. … Second or third line …
[HTML][HTML] 抗体偶联药物在肺癌中的研究进展与展望
朱以香， 王志杰 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… 研究显示，19%的NSCLC存在HER3过表达，腺癌可达46% [25] ，而且HER3还介导了EGFR-酪
氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）的耐药 [26] 。Patritumab Deruxtecan（U3-1402…
氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）的耐药 [26] 。Patritumab Deruxtecan（U3-1402…
[HTML][HTML] 2021 年非小细胞肺癌重要临床研究纵观与解读
甘彬， 刘思阳， 吴一龙 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… 表皮生长因子受体抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI）用
于EGFR突变NSCLC患者术后辅助治疗的策略已纳入中国临床肿瘤学会（Chinese Society …
于EGFR突变NSCLC患者术后辅助治疗的策略已纳入中国临床肿瘤学会（Chinese Society …
宫颈癌分子靶向治疗的研究进展
杨莉， 程玺 - 中国癌症杂志, 2015 - china-oncology.com
… 子VEGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs). … study of pazopanib or lapatinib
monotherapy in patients with … A phase Ⅱ trial to evaluate gefitinib as second- or third-line …
monotherapy in patients with … A phase Ⅱ trial to evaluate gefitinib as second- or third-line …